Idexx LaboratoriesIDXX财报
Nasdaq · 医疗保健 · 医疗保健设备
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
IDXX 2025财年Q4 Key Financial Metrics
营收
$1.1B
毛利润
$658.1M
营业利润
$315.6M
净利润
$248.2M
毛利率
60.3%
营业利润率
28.9%
净利率
22.8%
同比增长
14.3%
EPS
$3.09
Idexx Laboratories 2025财年Q4 财务摘要
Idexx Laboratories 2025财年Q4营收 $1.1B（同比增长 14.3%），净利润 $248.2M（同比增长 14.8%）（净利率 22.8%）。销售成本 $432.5M，运营费用 $342.5M。
核心财务指标
| 总营收 | $1.1B |
|---|---|
| 净利润 | $248.2M |
| 毛利率 | 60.3% |
| 营业利润率 | 28.9% |
| 报告期 | 2025财年Q4 |
营收拆解
Idexx Laboratories 2025财年Q4营收 $1.1B 共来自 11 个业务板块，最大板块 Vet Lab Consumables 贡献 $389.0M（占 35.7%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Vet Lab Consumables | $389.0M | 35.7% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32.0% |
| Rapid Assay Products | $76.0M | 7.0% |
| Recurring Revenue | $70.6M | 6.5% |
| CAG Diagnostic Capital Instruments | $58.1M | 5.3% |
| Water Segment | $50.5M | 4.6% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3.4% |
| CAG Diagnostics Service And Accessories | $35.3M | 3.2% |
| Systems And Hardware | $20.1M | 1.8% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0.2% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0.1% |
Idexx Laboratories 分部营收 — 季度趋势
Idexx Laboratories 过去 4 个季度各业务板块营收走势，展示 Vet Lab Consumables和Reference Laboratory Diagnostic And Consulting Services 等业务的变化。
| 业务分部 | 2025财年Q4 | 2025财年Q3 | 2025财年Q2 | 2025财年Q1 |
|---|---|---|---|---|
| Vet Lab Consumables | $389.0M | $387.8M | $375.1M | $344.8M |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | $362.7M | $367.7M | $344.4M |
| Rapid Assay Products | $76.0M | $88.6M | $100.2M | $84.0M |
| Recurring Revenue | $70.6M | $71.0M | $69.0M | $65.8M |
| CAG Diagnostic Capital Instruments | $58.1M | $51.5M | $58.6M | $32.0M |
Idexx Laboratories 年度营收
Idexx Laboratories 历年营收汇总，含各年度总量（例如 2025 年营收为 $4.3B）
Idexx Laboratories 季度营收与净利润历史
Idexx Laboratories 最近 8 个季度的营收、净利润及同比增速
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| 2025财年Q4 | $1.1B | +14.3% | $248.2M | 22.8% |
| 2025财年Q3 | $1.1B | +13.3% | $274.6M | 24.8% |
| 2025财年Q2 | $1.1B | +10.6% | $294.0M | 26.5% |
| 2025财年Q1 | $998.4M | +3.6% | $242.7M | 24.3% |
| 2024财年Q4 | $954.3M | +5.8% | $216.1M | 22.7% |
| 2024财年Q3 | $975.5M | +6.6% | $232.8M | 23.9% |
| 2024财年Q2 | $1.0B | +6.4% | $203.3M | 20.3% |
| 2024财年Q1 | $964.1M | +7.1% | $235.6M | 24.4% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $964.1M | $1.00B | $975.5M | $954.3M | $998.4M | $1.11B | $1.11B | $1.09B |
| 同比增长 | 7.1% | 6.4% | 6.6% | 5.8% | 3.6% | 10.6% | 13.3% | 14.3% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $3.35B | $3.41B | $3.35B | $3.29B | $3.21B | $3.33B | $3.39B | $3.35B |
| 总负债 | $1.78B | $1.83B | $1.73B | $1.70B | $1.77B | $1.87B | $1.83B | $1.75B |
| 股东权益 | $1.57B | $1.58B | $1.62B | $1.60B | $1.45B | $1.46B | $1.56B | $1.61B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $198.6M | $248.3M | $220.1M | $262.0M | $238.0M | $185.7M | $402.3M | $355.8M |